Disappointing. Latest CE Mark guesstimate was end-2017, now looks like mid-2018 at best. Only guarantee is that any revenues from CE Mark certification will arrive too late to avoid another "working capital" capital raise, as only $2m in cash reserves forecast by end-March.
So looks like:
1. Raise more funds to get through to CE Mark.
2. Hopefully get CE Mark and start making sales.
3. Raise further funds to execute OncoPac-1.
Its going to be a hard task raising funds for 1, given the shredded credibility with the whole CE Mark 5+ year debacle. No guarantee the company will ever get to 3.
Looks too risky now ...
OSL Price at posting:
14.0¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)